Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A synonymous EGFR polymorphism predicting responsiveness to anti-EGFR therapy in metastatic colorectal cancer patients.

Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine - 1 Jun 2016

Bonin Serena, Donada Marisa, Bussolati Gianni, Nardon Ermanno, Annaratone Laura, Pichler Martin, Chiaravalli Anna Maria, Capella Carlo, Hoefler Gerald, Stanta Giorgio

Abstract excerpt

Genetic factors are known to affect the efficiency of therapy with monoclonal antibodies (mAbs) targeting the epidermal growth factor receptor (EGFR) in patients with metastatic colorectal cancer (mCRC). At present, the only accepted molecular marker predictive of the response to anti-EGFR mAbs is the somatic mutation of KRAS and NRAS as a marker of resistance to anti-EGFR. However, only a fraction of KRAS...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Camptothecin
Share to Cetuximab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to Fluorouracil

Share to Genes, erbB-1

Share to Irinotecan

Share to Leucovorin

Share to Panitumumab

Source

Identifiers

PMID: 26666825
DOI: 10.1007/s13277-015-4543-3

Genes

EGFR
KRAS
NRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A synonymous EGFR polymorphism predicting responsiveness to anti-EGFR therapy in metastatic colorectal cancer patients.PMID 26666825Read ↗

Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer.Semantic proximity Read ↗

Synonymous EGFR variant p.Q787Q is neither prognostic nor predictive in patients with lung adenocarcinoma.Semantic proximity Read ↗

Letter to the editor: Worse prognosis caused by anti-EGFR treatment in advanced colorectal cancer patients with KRAS mutation.Semantic proximity Read ↗

Patient-tailored treatments with anti-EGFR monoclonal antibodies in advanced colorectal cancer: KRAS and beyond.Semantic proximity Read ↗

The Best. First. Anti-EGFR before anti-VEGF, in the first-line treatment of RAS wild-type metastatic colorectal cancer: from bench to bedside.Semantic proximity Read ↗

Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).Semantic proximity Read ↗

The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer.Semantic proximity Read ↗

Potential predictive markers of response to EGFR-targeted therapies in colorectal cancer.Semantic proximity Read ↗

Association of candidate single nucleotide polymorphisms with somatic mutation of the epidermal growth factor receptor pathway.Semantic proximity Read ↗

The EGFR pathway as an example for genotype: phenotype correlation in tumor genes.Semantic proximity Read ↗

A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy.Semantic proximity Read ↗

The EGFR R521K polymorphism influences the risk to develop colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.